Zuyderland Medisch Centrum
Welcome,         Profile    Billing    Logout  
 11 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kietselaer, Bas
NCT02381301: Biomarkers and Cardiac CT

Recruiting
N/A
5000
Europe
Venous blood sampling prior to CCTA.
Maastricht University Medical Center
Coronary Artery Disease, Atherosclerosis
12/29
12/29
Erdkamp, F L
LyRICX, NCT03764553: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Recruiting
2
320
Europe
Liposomal Irinotecan, Carboplatin, Capecitabine, Xeloda, Oxaliplatin, 5-fluorouracil, Leucovorin
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Servier
Esophageal Cancer
07/25
07/26
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Kuy, Hugo van der
SWITCH, NCT04927936 / 2021-000701-24: A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the Trial

Recruiting
N/A
432
Europe
Vaccination once with Janssen vaccine (only priming), Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting)., Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting)., Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).
Erasmus Medical Center, Leiden University Medical Center, University Medical Center Groningen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Covid19
09/22
09/22
SWITCH _ON, NCT05471440 / 2022-002560-73: SWITCH ON: Analysing the Immunogenicity of Additional Booster Vaccinations in HCW

Active, not recruiting
N/A
431
Europe
Direct boost mRNA, Direct boost adeno, Post-poned boost mRNA, Post-poned boost adeno
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Leiden University Medical Center, University Medical Center Groningen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Covid-19 Vaccination
09/22
08/23
Bastelaar, James van
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
3
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34
LAUREN, NCT05509829: EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery

Recruiting
N/A
300
Europe
Negative pressure wound therapy
Zuyderland Medisch Centrum
Breast Cancer, Seroma, Wound Complication
09/23
12/23
SARA, NCT04035590: Seroma Reduction and Drain Free Mastectomy

Recruiting
N/A
250
Europe
No drain, With drain
Zuyderland Medisch Centrum
Breast Cancer, Seroma, Wound Complication
12/23
12/23
SCARLETT, NCT05145829: Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients

Recruiting
N/A
40
Europe
Diagnostic Test: Sentinel node mapping using MRI
Zuyderland Medisch Centrum
Melanoma
09/24
09/24
Cruijsen, H van
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Garus, Veronika
No trials found
Kampen, RJW van
No trials found
Hendriks, Han
No trials found
Lecomte, Frederique
No trials found
sub-investigator, Site
No trials found

Download Options